Ascletis’ Gannex reports positive interim PhII NASH data after scrapping previous mid-stage R&D plansnews2024-01-02T12:52:57+00:00January 2nd, 2024|Endpoints News|
Novartis doubles down on neurologic gene therapy work with Voyagernews2024-01-02T12:34:45+00:00January 2nd, 2024|Endpoints News|
ImmunityBio inks royalty deal, private placement to raise $210M for bladder cancer drug combonews2024-01-02T12:30:42+00:00January 2nd, 2024|Endpoints News|
Exclusive: Tome acquires Replace Therapeutics for DNA ligase technologynews2024-01-02T12:00:25+00:00January 2nd, 2024|Endpoints News|
Verona secures $400M financing arrangement with Oxford, Hercules as ensifentrine PDUFA date inches closernews2024-01-02T10:56:00+00:00January 2nd, 2024|Endpoints News|
Edgewise boosts awareness of rare Becker muscular dystrophy as it pursues potential first therapynews2023-12-29T13:22:28+00:00December 29th, 2023|Endpoints News|
Novartis highlights the power of language in ‘My Cancer, My Words’ campaignnews2023-12-29T13:13:59+00:00December 29th, 2023|Endpoints News|
Health insurer and provider Devoted Health raises $175Mnews2023-12-29T13:00:02+00:00December 29th, 2023|Endpoints News|
FDA seizes thousands of counterfeit Ozempic units, warns consumers not to usenews2023-12-28T17:07:46+00:00December 28th, 2023|Endpoints News|
Zealand drug hit with CRL for ultra-rare disease amid manufacturing concerns, plans to resubmit in 2024news2023-12-28T16:04:51+00:00December 28th, 2023|Endpoints News|
